Since the discovery of the anti-dyskinetic properties of amantadine, there has been a renewed interest in its use. To evaluate its efficacy and tolerability, we performed a retrospective study of consecutive patients with Parkinson's disease (PD) who had received amantadine either as mono- or combination therapy for a 3-year period. We identified 41 patients. Nineteen (46%) experienced amantadine-related side effects. Eleven (27%) discontinued treatment before 1 year. Although dyskinesias improved (to some extent) in all patients after amantadine treatment, only 73.3% experienced improvement of motor symptoms. In conclusion, amantadine was effective in the treatment PD for at least 1 year in 40% of our patients.
|Original language||English (US)|
|Number of pages||6|
|Journal||Journal of Applied Research|
|State||Published - Nov 21 2006|
- Clinical practice
ASJC Scopus subject areas